Empiece
AlenCiken

$PRQR Announces Positive Results from Clinical Trial of QR-421a

ProQR Therapeutics N.V. (NASDAQ:PRQR)  
AlenCiken Actualizado   
NASDAQ:PRQR   ProQR Therapeutics N.V.
Trend Analysis Chart Patterns Fundamental Analysis biotech biotechnology biotechstocks biotechs biotechstock biotehnology
1
0
trendanalysis chartpattern fundamental biotech biotechnology biotechstocks biotechs biotechstock biotehnology
ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials.

QR-421a demonstrated a concordant benefit in multiple measures of vision, including best corrected visual activity (BCVA), static perimetry, and retinal imaging (OCT)

QR-421a observed to be well tolerated with no serious adverse events reported

Two pivotal Phase 2/3 trials are expected to start by the end of 2021

finance.yahoo.com/ne...nical-110000726.html
Comentarios:
Citigroup Reiterated buy $33 → $44
Exención de responsabilidad

La información y las publicaciones que ofrecemos, no implican ni constituyen un asesoramiento financiero, ni de inversión, trading o cualquier otro tipo de consejo o recomendación emitida o respaldada por TradingView. Puede obtener información adicional en las Condiciones de uso.